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Abstract
Background: The effects of ezetimibe on cholesterol metabolism in HIV-infected patients receiving boosted
protease inhibitors have not been thoroughly assessed. The aim of this study was to assess cholesterol homeostasis in
patients with PI associated dyslipidemia and its relationship with the response to treatment with the
cholesterol-absorption inhibitor ezetimibe.
Methods: Fifteen patients with ritonavir-boosted PI-containig therapy and LDL-cholesterol > 3.36 mmol/L (>130 mg/dL)
were assessed at baseline and after an 8-week course of ezetimibe 10 mg/d. Serum non-cholesterol sterols were
measured at each visit as markers of cholesterol synthesis and absorption. Total-, LDL-, and HDL-cholesterol triglycerides,
apolipoproteins A1 and B, high sensitivity C-reactive protein, CD4 cells and HIV-1 RNA were also measured.
Results: Ezetimibe treatment was well tolerated in all patients and resulted in significant reductions in total
cholesterol (−11.4%, p = .002), LDL-cholesterol (−20.4%, p = .003), non-HDL-cholesterol (−13.4%, p = .002) and
apolipoprotein B (−9.1%, p = .021).
Treatment with ezetimibe was associated with decreased cholesterol absorption markers (campesterol-to-cholesterol
ratio −43.0%, p = .001; sitosterol-to-cholesterol ratio −41.9%, p = .001) and increased synthesis markers (lathosterol-to-
cholesterol ratio 53.2%, p = .005). Baseline absorption or synthesis markers were unrelated to the response to treatment.
CD4 cell count and plasma HIV-1 RNA remained unchanged.
Conclusions: The level of cholesterol absorption or synthesis does not appear to be a major determinant of the
responsiveness to ezetimibe in patients on ritonavir-boosted PI-containing therapy.
Trial registration: EudraCT: 2006-006156-36
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Background
Abnormalities of lipid metabolism are common complica-
tions of HIV therapy, particularly with protease inhibitors
(PI) [1]. Antiretroviral treatment exposure is an independ-
ent risk factor for cardiovascular disease in HIV-infected
patients [2], which is particularly linked to PI exposure
and relates in part to lipid alterations [3]. This risk adds to
conventional risk factors, particularly smoking, which is
highly prevalent among seropositive patients [4]. In
addition, HIV-associated inflammation and vascular dys-
function may also lead to increased cardiovascular mor-
bidity despite successful antiretroviral therapy (ART) [5].
Although statins are considered the drugs of choice
for attaining LDL-cholesterol targets in HIV-infected pa-
tients [6], some statins may display clinically significant
interactions with common antiretroviral drugs through
inhibition of CYP3A metabolic pathways [7]. Further-
more statin therapy in HIV-infected patients has a lipid-
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lowering efficacy lower than expected, thus patients may
require high doses or additional cholesterol-lowering
agents [8]. Ezetimibe is a lipid lowering agent that re-
versibly inhibits intestinal cholesterol absorption with-
out interfering with hepatic P-450 enzymes [9], thus
showing a low potential for drug interactions com-
pared with currently available statins. As PI increase
cholesterol synthesis through activation of SREBP regu-
lated pathways [10], it is unknown whether the use of a
cholesterol-absorption inhibitor in HIV-infected patients
treated with PI induces different changes in cholesterol
metabolism than those reported in non-HIV infected dys-
lipidemic patients.
Small amounts of non-cholesterol sterols circulate in
blood and can be used as reliable biomarkers of choles-
terol metabolism [11]. Plasma cholesterol precursors
such as lathosterol are markers of cholesterol synthesis
and, when expressed as ratios to cholesterol, show a good
correlation with synthesis rates measured by isotope kinetic
techniques [12]. Plant sterols or phytosterols are absorbed
in the small bowel via the same receptor involved in choles-
terol absorption (NPC1L1) [13]. Therefore, plasma levels of
the main phytosterols, campesterol and sitosterol, can be
used as indicators of cholesterol absorption [8,14].
In general population with hypercholesterolemia, treat-
ment with ezetimibe resulted in decreased LDL-cholesterol
by −17 to −20% [15-17]. A reduction in campesterol/chol-
esterol and sitosterol/cholesterol ratios (−41 and −34%, re-
spectively), and an increase in lathosterol/cholesterol ratio
(+72%) has also been reported [15,17,18].
The aim of this study was to assess cholesterol homeo-
stasis in patients with PI-associated dyslipidemia and its




HIV-infected adults (≥18 years) receiving stable ritonavir-
boosted PI-containing ART, with plasma HIV-1 RNA
below 50 copies/ml at least for the previous 6 months, and
presenting with plasma LDL-cholesterol levels between
3.36 and 4.91 mmol/l (130–190 mg/dL) without statin
therapy were considered eligible for study. Exclusion cri-
teria were: hypersensitivity to ezetimibe, consumption of
phytosterol-enriched functional foods within one month
before study entry, prior history of cardiovascular disease,
secondary hypercholesterolemia, renal insufficiency (de-
fined by a glomerular filtration rate (MDRD) <60 mL/
min/1.73 m2), increased transaminase levels (defined by 5
times above the upper level of normality), concomitant
treatment for hepatitis virus coinfections, diabetes melli-
tus, active illicit drug or alcohol abuse, AIDS-defining op-
portunistic infection within 3 months prior to study
entry, any acute illness within one month prior to study
entry, and pregnancy or breastfeeding. Criteria for pa-
tient withdrawal from the study were any changes in
antiretroviral regimen during the study period, includ-
ing dose changes or drug discontinuation.
The study was approved by the institutional review
board of Hospital Clinic de Barcelona, and conducted ac-
cording to good practice guidelines. All patients provided
written informed consent before study entry.
Study design
In this open-label intervention study, participants re-
ceived ezetimibe 10 mg/d during 8 weeks. At study
entry, all patients received written recommendations to
ensure avoidance of phytosterol supplements during the
study period. Patients were scheduled for visits at base-
line and week 8. At each visit 3-day food records were
obtained and the nutrient composition of the diet was
assessed by using Food Process-Plus software (version
8.0). Spent boxes of medication were collected to assess
compliance. Anthropometric measurements were made
by standard methods. Waist circumference was mea-
sured in the upright position half way between the lower
subcostal margin and the iliac crest. Previous ART was
recorded as time of exposure to combination ART
(cART) as well as to thymidine and non-thymidine ana-
logues (TA) Reverse Transcriptase Inhibitors (RTI), PI,
and non-Nucleoside Reverse Transcriptase Inhibitors
(NNRTI) families.
Laboratory methods
Fasting blood samples were obtained at baseline and at the
end of the treatment period. Except for standard biochem-
istry and blood-cell analyses, serum samples were stored
at −80°C and analyzed at the end of the study. Total choles-
terol, triglycerides, and HDL-cholesterol [after precipitation
of apolipoprotein (apo) B–containing lipoproteins] were
determined by standard enzymatic methods in an auto-
matic analyzer DDPPII Hitachi (Roche, Basle, Switzerland),
using specific reagents (Boehringer-Mannheim, Mannheim,
Germany). LDL-cholesterol was calculated by using
the Friedewald equation. ApoAl and apoB were deter-
mined by using turbidimetry. Concentrations of vari-
ables reflecting glucose control and kidney and liver
function, i.e., fasting glucose, total bilirubin, aspartate ami-
notransferase, alanine transaminase, alkaline phosphatase,
γ-glutamyl transpeptidase, and creatinine were determined
on the automatic analyzer. Hematological variables (total
and differential white blood cell count, red blood cell
count, hemoglobin concentration, hematocrit, mean cor-
puscular volume, and platelet count and volume) were de-
termined on a Coulter counter.
Non-cholesterol sterols and high sensitivity C-reactive
protein (CRP) were determined in frozen samples of
whole serum. Plant sterols (campesterol and sitosterol)
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and the cholesterol precursor lathosterol were analyzed
by gas chromatography as previously described [19].
Briefly, epicoprostanol (2 μg) was added to serum
(0.1 ml) as internal standard. After alkaline hydrolysis,
extraction, and derivatization to trimethylsilyl ethers, the
sterols were quantified by gas chromatography on a 30 m
nonpolar capillary column (TRB-Esterol; Teknokroma,
Barcelona, Spain) with a Perkin-Elmer GC Autosystem
(Perkin-Elmer, Norwalk, CT, USA). Plant sterol and pre-
cursors concentrations are expressed as ratios to choles-
terol (μmol/mmol cholesterol). Inter- and intra-assay CVs
were 5.0% and 3.2% for lathosterol, 1.9% and 1.6% for
campesterol, and 2.0% and 1.8% for sitosterol, respectively.
CRP was determined by turbidimetry. The intra-assay co-
efficient of variation for CRP was 3.1%.
The number of CD4 T lymphocytes was measured by
flow cytometry. Plasma HIV-1 RNA was measured by a
PCR assay (Amplicor HIV Monitor, Roche Diagnostics
Systems, Branchburg, New Jersey, USA; lower limit of
detection 50 copies/mL).
Statistical analyses
The primary efficacy variable was the change in serum
LDL-cholesterol. Key secondary variables were changes in
other lipids, non-cholesterol sterols, and CRP. Variables
were described as medians and interquartile ranges. Out-
lier values of CRP (1.5 times the interquartilic range above
the median) were excluded from the analysis of CRP
response. A sample size of 15 evaluable patients was con-
sidered necessary to detect a decrease of at least 20% in
LDL-cholesterol, according to previous data [20], with
an 80% power and a significance level of 0.05, using a
two-sided test. We used the Wilcoxon rank test for
within-group comparisons and the Spearman’s rho test for
correlation between continuous variables. Analyses were
performed using SPSS software version 16.0.
Results
Baseline characteristics
Fifteen patients (9 men and 6 women, mean age
53 years) were included and eligible for analysis. Eight
Table 1 Baseline data and outcome variables in 15 patients treated with ezetimibe for 8 weeks
Variables Baseline Treatment % change P*
Dietary assessment
Total calories (kj/d) 8037 [6728–9033] 7657 [6841–11167] −4.7% .55
Total fat (g/d) 93 [76–105] 86 [83–115] −7.5% .53
Saturated fatty acids (g/d) 26 [17–31] 24 [19–32] −7.7% .94
Cholesterol (mg/d) 254 [223–340] 294 [247–346] 15.7 .81
Phytosterols (mg/d) 184 [141–211] 156 [129–193] −15.2% .09
Body weight (kg) 73.0 [61.2-80.1] 73.1 [63.9-80.8] 0.1% 1
Waist circumference (cm) 92.5 [85.7-96] 95.0 [88–100] 2.7% .55
Lipids and apos
Total cholesterol (mmol/L) 5.87 [5.46-6.54] 5.2 [4.89-5.61] −11.4% .002
LDL-cholesterol (mmol/L) 3.93 [3.46-4.27] 3.13 [2.95-3.44] −20.4% .003
nonHDL-cholesterol (mmol/L) 4.63 [4.29-5.30] 4.01 [3.59-4.42] −13.4% .002
HDL-cholesterol (mmol/L) 1.21 [1.11-1.47] 1.19 [1.03-1.34] −2.1% .11
Triglycerides (mmol/L) 1.64 [1.15-2.04] 1.42 [1.15-2.29] −13.1% .46
Apo A1 (g/L) 1.47 [1.39-1.53] 1.54 [1.44-1.59] 4.7% 1
Apo B (g/L) 1.21 [1.09-1.42] 1.10 [0.95-1.24] −9.1% .02
C-reactive protein (mg/L) 1.2 [0.4-1.6] 0.6 [0.5-3.5] −50% .61
Plasma viral load (copies/mL) 49 [49–49] 49 [49–49] 0% .65
CD4 cell count (cells/μL) 503 [353–802] 499 [323–794] −0.8% .65
Lathosterol (μmol/L) 7.08 [5.19-9.43] 9.97 [6.68-12.67] 40.9% .015
Lathosterol/cholesterol 1.26 [0.84-1.54] 1.93 [1.37-2.40] 53.2% .005
Campesterol (μmol/L) 27.78 [20.22-38.95] 14.78 [10.72-18.51] −46.8% .001
Campesterol/cholesterol 4.65 [3.23-6.36] 2.62 [1.98-3.53] −43.6% .001
Sitosterol (μmol/L) 22.96 [20.34-33.25] 14.77 [10.96-19.52] −35.7% .001
Sitosterol/cholesterol 4.46 [3.70-6.09] 2.59 [2.17-3.76] −41.9% .001
Results are expressed as medians [IQR]. *Wilcoxon Rank test.
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patients were active smokers. Median ART exposure
was 504 w (range 228–581). Median exposures to spe-
cific therapies were: non-TA RTI, 449 w; TA RTI, 303
w; PI, 350 w, and NNRTI, 32 w. Intake of selected
nutrients did not change between time points. The
intervention had no effect on body weight or waist cir-
cumference (Table 1).
Efficacy
After 8 weeks of ezetimibe treatment, significant changes from
baseline were observed for total cholesterol (−0.67 mmol/L;
p = .002), LDL-cholesterol (−0.80 mmol/L; p = .003), non-
HDL-cholesterol (−0.62 mmol/L; p = .002) and apoB
(−0.11 g/L; p = .021). No significant changes were ob-
served for HDL-cholesterol, triglycerides, apoA1 or
CRP (Table 1). Total cholesterol and LDL-cholesterol
responses were consistent in most patients (Figure 1).
Treatment with ezetimibe was associated with a re-
duction in plasma campesterol and sitosterol concentra-
tions in every participant, which confirms participants’
compliance with the study drug. Similar results were
observed for their ratios to cholesterol. Conversely,
plasma lathosterol increased in most treated subjects
(Table 1, Figure 1).
Concerning safety, CD4 cell count and plasma HIV-1
RNA remained unchanged. No changes in routine bio-
chemistry or hematologic parameters were observed.
Relationship between markers of cholesterol metabolism
and response to treatment
Baseline campesterol- and sitosterol-to-cholesterol ra-
tios (as markers of absorption) and the lathosterol-to-
cholesterol ratio (as a marker of synthesis) were not
associated with the cholesterol lowering response to
ezetimibe, as judged by the lack of correlation between
these variables and changes in LDL-cholesterol after
treatment. No correlation was observed either between
baseline lipid levels and these markers.
Baseline campesterol- and sitosterol-to-cholesterol ratios
were highly correlated between them (r = .932; p < .001). Al-
though lathosterol-to-cholesterol ratio increased as ex-
pected in response to cholesterol absorption inhibition, the
changes were unrelated to those of either campesterol or si-
tosterol. Changes in CRP did not correlate with changes in
plasma lipids or non-cholesterol sterols.
Previous antiretroviral exposure (total cART or sub-
families: TA- and non-TA-RTI, PI, NNRTI) did not show
any correlation with markers of cholesterol absorption
or synthesis. No association existed between antiretro-
viral exposure and baseline lipid levels either.
Discussion
In this study we confirmed that 8 weeks of ezetimibe
monotherapy was effective in reducing total and LDL-
cholesterol in HIV patients receiving boosted-PI containing
ART. The reduction in LDL-cholesterol levels (−20.4%) was
Figure 1 Individual changes in total cholesterol, lipoprotein cholesterol and non-cholesterol sterols after ezetimibe treatment.
Leyes et al. BMC Infectious Diseases 2014, 14:497 Page 4 of 6
http://www.biomedcentral.com/1471-2334/14/497
in the expected range of responses reported in studies of
ezetimbe monotherapy in the general population with dys-
lipidemia (−16% to −20%) [15-17], as well as in HIV-
infected patients [21]. According to our data, seropositive
patients receiving boosted-PI do not necessarily have a
weaker response to ezetimibe, as suggested by Wohl et al.
[20]. These authors found a poor response to ezetimibe
(−5.3% LDL-cholesterol reduction) in HIV patients on
triple therapy, but their mean baseline LDL-cholesterol
(3.31 mmol/L) was lower than that in our population,
which could account, at least in part, for the differences
observed.
However, despite its efficacy in reducing serum choles-
terol levels, the effectiveness of ezetimibe in reducing
major cardiovascular events is yet to be proven. There is
an ongoing clinical trial (IMPROVE-IT; ClinicalTrials.
gov identifier NCT00202878) addressing this issue.
In our study ezetimibe resulted in a reduction in choles-
terol absorption markers and an increase in cholesterol
synthesis markers, which were in the range of the changes
reported in non-HIV dyslipidemic subjects [15,17,18], sug-
gesting that PI-containing ART has no major effect on
cholesterol absorption or synthesis. However, the level of
cholesterol absorption does not appear to be a major de-
terminant of the responsiveness to ezetimibe, as shown by
the lack of correlation between cholesterol absorption or
synthesis markers and baseline lipid levels or their re-
sponse to therapy. Other studies in non-HIV hypercholes-
terolemic subjects have produced similar results [22,23]. In
one study, only a weak inverse correlation (r: −0.17) was
found between baseline campesterol-to-lathosterol ratio
and the response to ezetimibe [18]. In our study, neither
baseline sitosterol- nor campesterol-to-lathosterol ratios
correlated with response to therapy (data not shown). It is
possible that factors downstream the primary site of action
of ezetimibe could be major determinants of response.
In our study CRP decreased non-significantly after ezeti-
mibe treatment. The great intra- and inter-individual vari-
ability observed with this marker makes it difficult to
detect changes, at least in small studies. In a meta-analysis
assessing the contribution of LDL-dependent effects of
cholesterol-lowering therapies to changes in CRP, most of
the CRP reduction was related to LDL changes [24]. As
noted above, the small sample size is one limitation of our
study, particularly for secondary outcomes. However, the
study population was quite homogeneous for antiretroviral
therapy and viral control, ruling out any potential influ-
ence of antiretroviral changes or uncontrolled HIV repli-
cation on the results.
Conclusions
The pharmacological inhibition of cholesterol absorption
by ezetimibe is followed by a compensatory increase in
cholesterol synthesis. The level of cholesterol absorption
or synthesis prior to therapy does not appear to be a
major determinant of the responsiveness to ezetimibe.
Our findings in HIV patients receiving ritonavir-boosted
PI-containing therapy are similar to those reported in
non-HIV hypercholesterolemic subjects, suggesting that
therapy with protease inhibitors by itself does not sub-
stantially affect cholesterol homeostasis.
Abbreviations
ART: Antiretroviral therapy; cART: Combination ART; CRP: C-reactive protein;
NPC1L1: Niemann-Pick C1-Like 1; PI: Protease inhibitors; RTI: Reverse
Transcriptase Inhibitors; SREBP: Sterol regulatory element-binding protein;
TA: Thymidine analogues.
Competing interests
The authors declare that they have no competing interests. The study drug
ezetimibe was generously supplied by Merck Sharp & Dohme (MSD), Spain.
MSD had no role in study design, data collection, analysis, and interpretation,
or writing of the report.
Authors’ contributions
PL participated in study design, data monitoring, data analysis, and writing
of the manuscript. EM participated in study design, recruitment, data
monitoring, data analysis, and writing of the manuscript. ML participated in
recruitment and data monitoring. MC: carried out laboratory analysis of
non-cholesterol esterols and CRP. JT and AP: carried out dietary counselling
and analysis of dietary data. MF: participated in writing of the manuscript. ER
participated in design, data analysis, writing and revision of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
Emili Corbella provided expert assistance with statistical analyses. CIBERobn
is an initiative of ISCIII. The study was supported in part by grant FIS PS09/
01292, ISCIII, Spain.
Author details
1Endocrinology and Nutrition Service, Hospital Clínic, Universitat de
Barcelona, Villarroel 170, Barcelona 08036, Spain. 2Infectious Diseases Unit,
Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital
Clínic, Villarroel 170, Barcelona 08036, Spain. 3Lipid Clinic, IDIBAPS, Hospital
Clínic, Villarroel 170, Barcelona 08036, Spain. 4CIBER Fisiopatología de la
Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII), Madrid,
Spain. 5Fundació Clinic per la Recerca Biomèdica, Hospital Clínic, Villarroel
170, Barcelona 08036, Spain.
Received: 3 July 2014 Accepted: 2 September 2014
Published: 11 September 2014
References
1. Carr A, Samaras KM, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA:
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor
associated lipodystrophy, hyperlipidaemia, and diabetes mellitus:
a cohort study. Lancet 1999, 353:2093–99.
2. Friis-Møller N, Sabin CA, Weber R, Monforte A, El-Sadr WM, Reiss P, Thiébaut
R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN,
Lundgren JD: Combination antiretroviral therapy and the risk of
myocardial infarction. N Engl J Med 2003, 349:1993–2003.
3. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-
Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren
JD: Class of antiretroviral drugs and the risk of myocardial infection. N
Engl J Med 2007, 356:1723–1735.
4. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, Monforte A, Pradier C,
Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN,
Lundgren JD, DAD study group: Cardiovascular disease risk factors in HIV
patients – association with antiretroviral therapy. Results from the DAD
study. AIDS 2003, 17:1179–93.
5. Baker JV, Henry WK, Neaton JD: The consequences of HIV infection and
antiretroviral therapy use for cardiovascular disease risk: shifting
paradigms. Curr Opin HIV AIDS 2009, 4:176–182.
Leyes et al. BMC Infectious Diseases 2014, 14:497 Page 5 of 6
http://www.biomedcentral.com/1471-2334/14/497
6. The EACS executive committee,Guidelines. Prevention and management of
noninfectious co-morbidities in HIV; [http://www.eacsociety.org/Guidelines.aspx]
7. Ray GM: Antiretroviral and Statin Drug-Drug Interactions. Cardiol Rev
2009, 17:44–47.
8. Silverberg MJ, Leyden W, Hurley L, Go AS, Quesenberry CP Jr, Klein D,
Horberg MA: Response to newly prescribed lipid-lowering therapy in
patients with and without HIV infection. Ann Intern Med 2009, 150:301–313.
9. Van Heek M, Davis H: Pharmacology of ezetimibe. Eur Heart J 2002,
4(suppl J):J5–J8.
10. Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism.
Prog Lipid Res 2003, 42:81–92.
11. Miettinen TA, Tilvis RS, Kesäniemi YA: Serum plant sterols and cholesterol
precursors reflect cholesterol absorption and synthesis in volunteers of a
randomly selected male population. Am J Epidemiol 1990, 131:20–31.
12. Matthan NR, Raeini-Sarjaz M, Lichtenstein AH, Ausman LM, Jones PJ: Deuterium
uptakes and plasma cholesterol precursor levels correspond as methods for
measurement of endogenous cholesterol synthesis in hypercholesterolemic
women. Lipids 2000, 35:1037–44.
13. Von Bergmann K, Sudhop T, Lütjohann D: Cholesterol and plant sterol
absorption: recent insights. Am J Cardiol 2005, 96(suppl):10D–14D.
14. Sudhop T, Lütjohann D, von Bergmann K: Sterol transporters: targets of
natural sterols and new lipid lowering drugs. Pharmacol Ther 2005,
105:333–41.
15. Sudhop T, Lüthohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I,
von Bergmann K: Inhibition of intestinal cholesterol absorption by
ezetimibe in humans. Circulation 2002, 106:1943–1948.
16. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B,
Veltri EP, Ezetimibe Study Group: Efficacy of a potent new selective
cholesterol absorption inhibitor, ezetimibe, in patients with primary
hypercholesterolemia. Am J Cardiol 2002, 90:1092–1097.
17. Hiramitsu S, Ishiguro Y, Matsuyama H, Yamada K, Kato K, Noba M, Uemura
A, Yoshida S, Matsubara Y, Kani A, Hasegawa K, Hishida H, Ozaki Y: The
effects of ezetimibe on surrogate markers of cholesterol absorption and
synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb
2010, 17:106–114.
18. Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP:
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin
therapies on non-cholesterol sterols in patients with primary
hypercholesterolemia. Curr Med Res Opin 2008, 24:249–259.
19. Escurriol V, Cofán M, Moreno-Iribas C, Larrañaga N, Martínez C, Navarro C,
Rodríguez L, González CA, Corella D, Ros E: Phytosterol plasma concentrations
and coronary heart disease in the prospective Spanish EPIC population
study. J Lipid Res 2010, 51:618–624.
20. Wohl DA, Waters D, Simpson RJ Jr, Richard S, Schnell A, Napravnik S, Keys J,
Eron JJ Jr, Hsue P: Ezetimibe alone reduces low-density lipoprotein
cholesterol in HIV-infected patients receiving combination antiretroviral
therapy. Clin Infect Dis 2008, 47:1105–8.
21. Coll B, Aragonés G, Parra S, Alonso-Villaverde C, Masana L: Ezetimibe effectively
decreases LDL-cholesterol in HIV-infected patients. AIDS 2006, 20:1675–7.
22. Lakoski SG, Xu F, Vega GL, Grundy SM, Chandalia M, Lam C, Lowe RS,
Stepanavage ME, Musliner TA, Cohen JC, Hobbs HH: Indices of cholesterol
metabolism and relative responsiveness to ezetemibe and simvastatin.
J Clin Endocrinol Metab 2010, 95:800–809.
23. Jakulj L, Vissers MN, Groen AK, Hutten BA, Lutjohann D, Veltri EP, Kastelein
JJ: Baseline cholesterol absorption and the response to ezetimibe/
simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J Lipid Res
2010, 51(4):755–62.
24. Kinlay S: Low-density lipoprotein-dependent and –independent effects of
cholesterol-lowering therapies on C-reactive protein. J Am Coll Cardiol
2007, 49:2003–2009.
doi:10.1186/1471-2334-14-497
Cite this article as: Leyes et al.: Effects of ezetimibe on cholesterol
metabolism in HIV-infected patients with protease inhibitor-associated
dyslipidemia: a single-arm intervention trial. BMC Infectious Diseases
2014 14:497.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Leyes et al. BMC Infectious Diseases 2014, 14:497 Page 6 of 6
http://www.biomedcentral.com/1471-2334/14/497
